In the BioHarmony Drug Report Database

"Preview" Icon

Aprepitant

Cinvanti, Emend (aprepitant) is a small molecule pharmaceutical. Aprepitant was first approved as Cinvanti on 2003-03-26. It has been approved in Europe to treat neoplasms, postoperative nausea and vomiting, and vomiting. The pharmaceutical is active against substance-P receptor. Emend’s patents are valid until 2035-09-18 (FDA).

 

Trade Name

 

Emend
 

Common Name

 

aprepitant
 

ChEMBL ID

 

CHEMBL1471
 

Indication

 

neoplasms, postoperative nausea and vomiting, vomiting
 

Drug Class

 

Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists

Image (chem structure or protein)

Aprepitant structure rendering